Seizert Capital Partners LLC Boosts Stock Position in United Therapeutics Corporation $UTHR

Seizert Capital Partners LLC lifted its position in United Therapeutics Corporation (NASDAQ:UTHR) by 2.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 125,541 shares of the biotechnology company’s stock after purchasing an additional 3,571 shares during the quarter. Seizert Capital Partners LLC owned about 0.28% of United Therapeutics worth $36,074,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. CWM LLC increased its stake in shares of United Therapeutics by 204.3% in the second quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock worth $1,492,000 after acquiring an additional 3,487 shares during the period. XTX Topco Ltd purchased a new stake in United Therapeutics in the first quarter valued at $313,000. Allianz Asset Management GmbH grew its position in United Therapeutics by 96.9% during the 1st quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company’s stock worth $20,832,000 after purchasing an additional 33,254 shares during the period. LPL Financial LLC grew its position in United Therapeutics by 77.3% during the 1st quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company’s stock worth $7,783,000 after purchasing an additional 11,007 shares during the period. Finally, Wealth Enhancement Advisory Services LLC raised its stake in shares of United Therapeutics by 77.4% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 6,084 shares of the biotechnology company’s stock valued at $1,792,000 after buying an additional 2,655 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on UTHR shares. Oppenheimer raised their target price on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. HC Wainwright raised their price objective on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Weiss Ratings reiterated a “buy (b-)” rating on shares of United Therapeutics in a research note on Thursday, November 13th. Morgan Stanley set a $447.00 target price on United Therapeutics in a research report on Wednesday, October 29th. Finally, Wells Fargo & Company boosted their price target on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $505.00.

United Therapeutics Price Performance

Shares of UTHR stock opened at $476.59 on Wednesday. The firm has a market cap of $20.52 billion, a PE ratio of 18.06, a price-to-earnings-growth ratio of 4.96 and a beta of 0.77. The company has a 50-day moving average of $435.39 and a two-hundred day moving average of $352.54. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $485.32.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The company had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. During the same quarter in the previous year, the company earned $6.39 earnings per share. The firm’s quarterly revenue was up 6.8% compared to the same quarter last year. Sell-side analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total transaction of $9,396,900.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 522,935 shares of company stock valued at $224,478,747 over the last ninety days. Company insiders own 10.30% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.